Fortis Healthcare signs 29-year deal for 400-bed Delhi hospital

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Fortis Healthcare signs 29-year deal for 400+ bed hospital in Delhi
  • Subsidiary FHTL provides clinical services and ₹567 crore loan
  • Hospital to offer tertiary care in oncology, cardiac, and neurosciences
  • Asset-light model expands Delhi-NCR footprint without fixed assets
powered bylight_fuzz_icon
51111861

*this image is generated using AI for illustrative purposes only.

Fortis Healthcare has signed definitive agreements with Seth Sunder Lal Jain Charitable Eye Hospital (SLJ Society) to provide healthcare services for a 400+ bed super specialty hospital in Ashok Vihar, New Delhi. The transaction is executed through its wholly owned subsidiary, Fortis Hospotel Limited (FHTL).

The healthcare services agreement grants FHTL exclusive rights to provide specified inpatient services and specialized equipment, including Cath Lab, LINAC, PET-CT, and surgical robots. The committed term is 29 years, with an option to extend on mutually agreed terms.

Deal Structure

Under the arrangement, SLJ Society will own, operate, and manage the hospital infrastructure, including land and building. FHTL will provide clinical manpower and healthcare services in consideration of an agreed service fee, calculated as a percentage of the revenue generated by the hospital.

FHTL has also agreed to provide a loan of up to ₹567 crore to SLJ Society for construction, upgradation, and operation of the facility. The loan will be disbursed in phased tranches over the next 3-4 years based on construction progress. SLJ Society has created appropriate security in favor of FHTL for this loan. FHTL will receive interest on the loan as per the loan agreement.

Operational Timeline

The hospital is expected to commence operations in 3-4 years, subject to necessary approvals. It will be developed on ~3.1 acres of land in North-West Delhi. The facility will offer tertiary and quaternary care across oncology, neurosciences, cardiac sciences, gastroenterology, orthopaedics, renal sciences, multi-specialty robotic surgeries, and transplants.

What the Numbers Show

The structure shifts capital expenditure risk to the partner while securing long-term revenue visibility for Fortis. By providing a ₹567 crore loan secured against the project rather than taking equity ownership, Fortis retains asset-light characteristics while locking in a 29-year service contract. This expands its Delhi-NCR footprint to more than 3,400 beds without adding fixed assets to its balance sheet.

Historical Stock Returns for Fortis Healthcare

1 Day5 Days1 Month6 Months1 Year5 Years
-1.11%-4.15%-6.32%+3.64%-10.98%+217.28%

How will the phased disbursement of the ₹567 crore loan impact Fortis Healthcare's near-term cash flow and debt-to-equity ratios over the next 3-4 years?

What are the potential credit risks associated with SLJ Society's ability to service the loan if the hospital faces delays in regulatory approvals or slower-than-expected patient volume post-launch?

How does this asset-light model compare to Fortis' traditional acquisition strategy in terms of long-term return on invested capital (ROIC) for this specific Delhi-NCR expansion?

Fortis Healthcare files Supreme Court petition against Delhi HC order

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Fortis Healthcare filed an SLP in the Supreme Court on September 16, 2026
  • The petition challenges a Delhi High Court judgment dated August 31, 2026
  • The case involves litigation with Daiichi Sankyo Company Limited
  • The company stated there are no expected financial implications
powered bylight_fuzz_icon
51082591

*this image is generated using AI for illustrative purposes only.

Fortis Healthcare filed a Special Leave Petition (SLP) before the Supreme Court of India on September 16, 2026. The move challenges an August 31, 2026 judgment by the Delhi High Court in ongoing litigation with Daiichi Sankyo Company Limited.

The filing, submitted at 2:54 am, pertains to specific applications within the case titled Daiichi Sankyo Company, Limited vs. Malvinder Mohan Singh And Ors. (O.M.P.(EFA)(COMM.) 6/2016). The applications involved are EX.APPL.(OS) 3764/2022, EX.APPL.(OS) 1615/2025, and EX.APPL.(OS) 3763/2022.

Regulatory Disclosure

The company made the disclosure pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This action follows earlier disclosures dated September 1, 2026, regarding the same legal matter.

Litigation Details

Particulars Details
Opposing Party Daiichi Sankyo Company Limited
Court Supreme Court of India (SLP filed against Delhi HC order)
Case Title Daiichi Sankyo Company, Limited vs. Malvinder Mohan Singh And Ors.
Financial Implications N/A
Quantum of Claims N/A

Fortis Healthcare stated that there are no expected financial implications or quantifiable claims associated with this specific filing. The company noted that details regarding the underlying order were previously disclosed to the exchanges.

Satyendra Chauhan, Company Secretary and Compliance Officer, signed the disclosure on behalf of the company.

Historical Stock Returns for Fortis Healthcare

1 Day5 Days1 Month6 Months1 Year5 Years
-1.11%-4.15%-6.32%+3.64%-10.98%+217.28%

How might the Supreme Court's eventual ruling on this SLP impact Fortis Healthcare's broader corporate governance structure and leadership stability?

Could the prolonged litigation with Daiichi Sankyo affect investor sentiment or credit ratings for Fortis Healthcare despite the stated lack of immediate financial implications?

What strategic advantages might Fortis gain if the Supreme Court overturns the Delhi High Court's judgment regarding the specific applications cited?

More News on Fortis Healthcare

1 Year Returns:-10.98%